{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273107","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.106195+00:00","generated_at":"2026-05-16T22:27:17.627056+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARS Pharma reports Q3 net loss $51.2M; neffy net product revenue $31.3M","bullets":["Q3 2025 total revenue $32.5M, including $31.3M neffy U.S. net product revenue; net loss $51.2M ($0.52/share).","SG&A expenses $74.8M, driven by DTC campaign; cash position $288.2M, including $100M term loan draw.","Over 18,000 HCPs have prescribed neffy (86% increase from Aug 2025); consumer awareness rose from 20% to 56%.","Japan approval for neffy in Sep 2025; U.K. launch of EUR neffy in Oct 2025; EU approval for 1 mg expected H1 2026.","Phase 2b urticaria trial enrolling; topline data anticipated mid-2026; company targets cash-flow breakeven."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273107","json":"https://secwatch.observer/filing/0001193125-25-273107.json","markdown":"https://secwatch.observer/filing/0001193125-25-273107.md","text":"https://secwatch.observer/filing/0001193125-25-273107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/0001193125-25-273107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000119312525273107/spry-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:27:17.627056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}